Abstract:
The present invention provides methods for the conversion of the thebaine to a morphine derivative, such as hydromorphone. Novel ketal intermediates to the conversion are provided. A one-pot procedure for the conversion comprises treating thebaine with an acid in the presence of a metal catalyst.
CONVERSION OF THEBAINE TO MORPHINE DERIVATIVES

FIELD OF INVENTION

[0001] The present invention relates to morphine-derived products. In particular, the invention relates to novel intermediates and methods for the synthesis of morphine derivatives.

BACKGROUND OF THE INVENTION

[0002] The supply of morphine and morphine-derived products in medicine depends on the isolation of major constituents of the opium poppy such as morphine 1, codeine 2 and thebaine 3, the structures of which are shown below.
[0003] The alkaloids are then converted by semi-synthesis to other medicinally useful agents such as hydrocodone 4, oxycodone 5, naltrexone 6, and naloxone 7.

[0004] Because of the commercial importance of these products, many attempts have been made to find an efficient method for their production. For example, United States Patent Application 2006/0167258 discloses a process for the manufacture of dihydrothebaine, dihydrocodeinone enol acetate, hydrocodone, and analogs thereof by reacting dihydrocodeine or analogs thereof with benzophenone in the presence of potassium tert-alkylate in a hydrocarbon solvent to generate a reaction mixture containing an enolate of the corresponding ketone, followed by addition of the reaction mixture to the electrophilic agent and isolation of the product. United States Patent No. 2006/0074239 discloses a method for the catalytic conversion of codeine, morphine or analogs thereof into hydrocodone, hydromorphone or analogs thereof utilizing a transition metal complex of a tertiary phosphine halide as catalyst. United States Patent Application 2003/0045720 discloses a method for the production of hydromorphone and hydrocodone from an alkaloid that comprises mixing the narcotic alkaloid with an acid in the presence of a catalyst wherein the method is carried out in the substantial absence of hydrogen gas. United States Patent No. 5,571685 discloses a method for the production of hydrocodone from neopinone or codeinone involving a morphinone reductase enzyme. Methods for the production of other derivatives can be found, for example, in United States Patent Nos. 6,235,906; 6,291,675; 6,864,370 and 7,129,248.

[0005] Thebaine is a particularly useful opiate alkaloid that can be converted into a variety of compounds such as hydrocodone, oxycodone, oxymorphone, nalbuphine, naloxone, naltrexone, buprenorphine and etorphine. The use of thebaine as a precursor alkaloid has been limited by the fact that it is a minor constituent of the latex obtained from the opium poppy. However, with the advent of genetically engineered plants, the content of thebaine in the latex may exceed 30%. Thebaine can be isolated as a major component from genetically altered plants introduced by Tasmanian Alkaloids and described in United States Patent No. 6,067,749.
Since thebaine can now be isolated in significant amounts, it could be an ideal starting material for the semi-synthetic opioid derivatives, such as hydrocodone and oxycodone. However, conversion of thebaine to the derivatives using current methods results in the production of undesirable intermediates. Recent recommendations from the ICH (International Conference on Harmonisation) recommend that the amount of α, β-unsaturated ketone containing compounds should be limited in pharmaceutical preparations (ICH Safety Guidelines, ICH S2A, 1995; ICH S2B, 1997). Thus, there has been an unmet need for new methods for the synthesis of morphine derivatives that avoid the production of such intermediates/impurities and that are cost efficient.

SUMMARY OF THE INVENTION

The present invention addresses the need for new methods for the synthesis of active morphine derivatives. According to the methods of the invention, thebaine is converted to a derivative such as hydrocodone. Variations of the method may also be used to convert thebaine to a C14 hydroxylated derivative. Novel ketal intermediates derived from thebaine are provided. These ketal intermediates play an important role in the conversion of thebaine to an active morphine derivative. A one-pot method for the conversion of thebaine to hydrocodone is also provided.

In a first aspect of the invention, a method of converting thebaine to a morphine derivative is provided. The method comprises the steps of: combining thebaine with an organic compound having at least one hydroxyl group in the presence of a catalyst to obtain a ketal intermediate; exposing the ketal intermediate to hydrogenation to obtain a hydrogenated intermediate; and hydrolyzing the hydrogenated intermediate to obtain a morphine derivative. Preferred morphine derivatives include hydrocodone and oxycodone, more preferably hydrocodone.

In a preferred embodiment, the hydrogenation and hydrolyzation steps are combined in a one-pot procedure.
Various types of organic compounds can be used in the methods of the invention. For example, the organic compound may be an aliphatic alcohol other than methanol or it may be a diol such as ethylene glycol or 2,3-dimethyl-1,4-butanediol.

In one preferred embodiment the catalyst is a protic or Lewis acid. A preferred acid catalyst is p-toluenesulfonic acid.

In another preferred embodiment, the catalyst is a metal catalyst. The catalyst is usually selected from the group consisting of: Pd, Pd(OAc), PdCl₂, PdBr₂, PdO, RhCl₃, PtO₂, RhCl₃(PPh₃)₃, Rh/Al, Pd/C, Pt/C, Pd on CaCO₃/Pb, Pd/Al, PtCl₂, PtCl₄, Al, Zn, Fe, Sn, Ru, Co, Rh, Ir, Ni, Pd, Pt, Ti, Os, Cu. Preferred catalysts include Pd(OAc)₂, PdCl₂, PdBr₂, PdO, RhCl₃, PtO₂, RhCl₃(PPh₃)₃, Rh/Al, Pd/C, Pt/C, Pd on CaCO₃/Pb (Lindlar), Pd/Al, PtCl₂, PtCl₄.

In another aspect of the invention, a ketal derivative obtained according to the methods of the invention is provided.

In a preferred embodiment, a ketal derivative of thebaine comprises a structure selected from the group below:

wherein V is C₂ - C₁₀ alkyl
W is H or C₁ - C₁₀ alkyl
X is H or C₁ - C₁₀ alkyl, cyclopropylmethyl, cyclobutylmethyl, propenyl, acyl (C₁ - C₁₀) or carboxy (C₁ - C₁₀)
Y is H or I or Br or Cl or F
R is H, alkyl (C₁ - C₁₀), hydroxyl alkyl (C₁-C₁₀), or alkoxo alkyl;
R₁ is H, alkyl (C₁ - C₁₀), hydroxyl alkyl (C₁-C₁₀), or alkoxo alkyl;
Z is O, S or N; and
wherein R and R1 may be the same or different.

[0015] Preferred ketal intermediates include the compounds shown below:

[0016] In a preferred embodiment the ketal derivative is an unsaturated ethylene glycol ketal of neopinone.

[0017] In another preferred embodiment, the ketal derivative is a halogenated ketal.

[0018] In another aspect of the invention, a hydrogenated ketal intermediate is provided.

[0019] In a preferred embodiment, the hydrogenated intermediate has the structure:

[0020] In yet another aspect of the invention, an alkyl ammonium salt of the ketal intermediate is provided.

[0021] In preferred embodiments, the salt is allyl derived or methylene cyclopropyl derived.
In a further aspect of the invention, a method of obtaining a morphine derivative from thebaine is provided. The method comprises: combining thebaine with an organic compound having at least one hydroxyl group in the presence of a pseudo-proton to obtain a ketal intermediate; and subjecting the intermediate to a one pot hydrogenation and hydrolysis to obtain the morphine derivative, preferably hydrocodone.

In a preferred embodiment, the pseudo proton is provided by a halogen selected from the group consisting of bromine, chlorine and iodine, preferably bromine.

In another preferred embodiment, the pseudo proton is provided by a transition metal catalyst.

In yet another aspect of the invention, a one pot method of obtaining hydrocodone from thebaine is provided that comprises exposing thebaine to Pd(OAc)₂ in the presence of an organic compound having at least one hydroxyl group. The organic compound having at least one hydroxyl group is preferably ethylene glycol.

In a further aspect of the invention a one pot method for the conversion of thebaine to hydrocodone comprises exposing thebaine to Pd(OAc)₂ in the presence of aqueous THF followed by hydrogenation.

In a further aspect, a one-pot method for obtaining hydrocodone from thebaine comprising exposing thebaine to an acid under about one atmosphere of hydrogen in the presence of a catalyst under aqueous conditions is provided. The acid typically comprises HCl or H₂SO₄.

In another aspect of the invention, a method of converting thebaine to a C₁₄ hydroxylated derivative, said method comprising the steps of:

i) exposing thebaine to an organic compound containing at least one hydroxyl group in the presence of a catalyst to obtain a ketal intermediate; subjecting the derivative to hydrogenation and hydrolysis; and
ii) oxidation of a hydrogen to a hydroxyl.

[0029] In a further aspect, there is provided a method of converting thebaine to a C14 hydroxylated derivative. The method comprises the steps of: exposing thebaine to an organic compound containing at least one hydroxyl group in the presence of a catalyst to obtain a ketal intermediate; converting the ketal to a 14-hydroxy ketal; and subjecting the 14-hydroxyketal to hydrolysis.

DETAILED DESCRIPTION

[0030] The present invention provides methods for the production of hydrocodone and analogs thereof using thebaine \((\text{C}_{19}\text{H}_{21}\text{NO}_3)\) as the starting material. The methods of the invention allow for the production of morphine derivatives in a rapid and cost-efficient manner.

[0031] While hydrocodone is a preferred ketone derivative obtained according to the methods of the invention, slight variations in the methods may yield other derivatives, such as oxycodone, naltrexone, naloxone, 14-hydroxycodinone, neopinone, hydromorphone, and oxymorphone. [The invention encompasses the production of these other derivatives from thebaine as well as novel derivatives obtained using the methods of the invention.

[0032] Methods of the invention for the conversion of thebaine to a ketone derivative may include the synthesis of a ketal intermediate, followed by hydrogenation and then hydrolysis. Alternatively, a one-pot procedure for the conversion of thebaine to hydrocodone may be used. Preferred embodiments of the methods are discussed below.

[0033] In a first aspect of the invention, thebaine is combined with an organic compound having at least one hydroxyl group, other than methanol, in the presence of catalyst and a novel ketal derivative is produced. The nature of the ketal derivative varies depending on the alcohol used. For example, exposure of thebaine to a 1,2 diol leads to the generation of a \(\beta,\gamma\) unsaturated ketal intermediate.

[0034] An exemplary reaction scheme is shown below:
[0035] Exposure of thebaine 3 to ethylene glycol in chloroform in the presence of TsOH led to smooth conversion to the corresponding ketal 10.

[0036] The Δ7,8 isomeric ketal was not detected in the reaction mixture. The ketal intermediate 10 was converted to a hydrogenated intermediate 13 under 1 atmosphere of hydrogen. Subsequent hydrolysis resulted in the production of hydrocodone 4. Ketal 10 can also be directly converted to 4 using a one pot hydrogenation and hydrolysis procedure.

[0037] Alternative conditions for the collapse of the enol ether of thebaine in order to generate 10 were also investigated. Several exemplary reactions are shown below.
In one of the illustrated schemes, bromine is used as a 'pseudo-proton'. In the presence of ethylene glycol an intermediate, ketal 14 is formed. This ketal intermediate is, in turn, converted to hydrocodone by hydrogenation and hydrolysis. While bromine was used in this example, other "pseudo-protons" can also be used. For example, other halogens as well as metal catalysts can be substituted.

The previously unidentified \( \beta, \gamma \), unsaturated ketals, such as neopinone ketals 10 and 14, are valuable intermediates for the synthesis of various opiate ketone derivatives not just hydrocodone. For example, ketal 10 can be used as a precursor to a C14 hydroxylated species, via functionalization of the olefin moiety. This methodology can be used to produce, for example, oxycodone or oxymorphone.

In a modified method of the invention shown above, the use of Pd(OAc)\(_2\), in the presence of ethylene glycol provides the dual purpose of initially providing a
proton surrogate and later acts as a hydrogenation catalyst. The intermediate 15 is rapidly converted to hydrocodone. Using this procedure hydrocodone was obtained in a one-pot sequence from thebaine.

[0041] In another variation of the method, thebaine is treated in aqueous THF with Pd(OAc)$_2$. This rapidly leads to the intermediate 16, which is immediately treated with 1 atmosphere of hydrogen to yield hydrocodone 4. This provides a rapid, efficient method for the production of hydrocodone from thebaine.

[0042] Although Pd(OAc)$_2$ was used in these reactions, it is apparent that other catalyst could also be used.

[0043] The present invention also provides a method for a one step conversion of thebaine to hydrocodone in the presence of a catalyst. The catalyst can be any metal from the platinum group (Ru, Rh, Pd, Os, Ir, Pt) which may or may not be on a solid support such as C, Al, Al$_2$O$_3$, SiO$_2$, etc. In a preferred embodiment, shown below, treatment of thebaine in an aqueous acid such as HCl or H$_2$SO$_4$ under about 1 atmosphere of hydrogen in the presence of Pd/C (10%) provides hydrocodone 4.

[0044] The above disclosure generally describes the present invention. It is believed that one of ordinary skill in the art can, using the preceding description, make and use the compositions and practice the methods of the present invention. A more complete understanding can be obtained by reference to the following specific examples. These examples are described solely to illustrate preferred embodiments of the present invention and are not intended to limit the scope of the invention. Changes in form and substitution of equivalents are contemplated as circumstances may suggest or render expedient. Other generic configurations will be apparent to one skilled in the art. All journal articles and
other documents such as patents or patent applications referred to herein are hereby incorporated by reference.

EXAMPLES

[0045] Although specific terms have been used in these examples, such terms are intended in a descriptive sense and not for purposes of limitation. Methods of chemistry referred to but not explicitly described in the disclosure and these examples are reported in the scientific literature and are well known to those skilled in the art.

Example 1. Neopinone ethylene glycol ketal (10)

[0046] Thebaine (500 mg, 1.6 mmol, 1.0 eq) was dissolved in CHCl₃ (0.9 ml) and ethylene glycol (1.0 g, 16.1 mmol, 10.0 eq) added. To this biphasic solution under vigorous stirring was added TsOHNaO₂ (1.0 g, 5.3 mmol, 3.3 eq). The reaction was heated to reflux for 45 minutes, cooled to 0 °C and the pH adjusted to >11 using saturated aqueous K₂CO₃ or ammonium hydroxide. Extraction of the reaction solution with CHCl₃ (5 ml x 3), drying over Na₂SO₄ and filtration provided a dark yellow residue. Purification by silica gel chromatography (CHCbMeOH/H₂O 98:2:1) provides the title product as a pale yellow oil in 38% yield.

[0047] FTIR (ν max cm⁻¹) film: 3407, 3031, 2924, 2903, 2833, 2791, 1634, 1603, 1504, 1448, 1325, 1277, 1258, 1165, 1050, 1035, 825; ¹H NMR (CDCl₃, 600 MHz): 6.74 (d, J = 8.2 Hz, 1H), 6.64 (d, J = 8.2 Hz, 1H), 5.56 (d, J = 5.6 Hz, 1H), 4.70 (s, 1H), 4.28 (q, J = 6.2 Hz, 1H), 3.93 (q, J = 6.8 Hz, 1H), 3.86 - 3.90 (m, 4H), 3.81 (q, J = 6.2 Hz, 1H), 3.64 (d, J = 3.64 Hz, 1H), 3.26 (d, J = 18.1 Hz, 1H), 2.67 - 2.78 (m, 2H), 2.61 (dd, J = 12.6, 4.6 Hz, 1H), 2.50 (d, J = 1.1 Hz, 1H), 2.47 (s, 3H), 2.14 (dd, J = 16.2, 6.4 Hz, 1H), 2.06 (td, J = 12.5, 5.0 Hz, 1H), 1.85 (dd, J = 12.3, 1.9 Hz, 1H); ¹³C NMR (CDCl₃, 125.5 MHz): 145.6, 142.1, 138.4, 131.8, 127.2, 119.4, 113.8, 113.2, 108.1, 93.1, 66.7, 65.4, 61.2, 56.8, 54.9, 45.8, 42.2, 36.2, 32.7, 26.8; MS (EI) m/z (%): 342 (23.1), 341 (100.0), 326 (10.0), 269 (10.6), 268 (21.24), 255 (17.5), 254 (52.4), 240 (10.0), 226 (14.5), 212 (11.1), 85 (22.2), 83 (34.4), 42 (18.4); HRMS (El) calcd for C₂₀H₂₃NO₄: 341.1627; found 341.1621
Example 2. Dihydrononepine ethylene glycol ketal (13)

[0048] A solution of 10 (100 mg, 0.3 mmol) in CHCl₃ (1 ml) was treated with Pt/C (10%) under 1 atmosphere of H₂ for 16 hours. Filtration through a plug of silica with CHCl₃/MeOH/NH₂O-I 92:8:1 gave the title compound in quantitative yield.

[0049] FTIR (ν max cm⁻¹) film: 2941, 2926, 2889, 1636, 1611, 1502, 1441, 1325. 1275, 1258, 1190, 1155, 1060, 922; ¹H NMR (CDCl₃, 600 MHz): 6.67 (d, J = 8.2 Hz, 1H), 6.55 (d, J = 8.2 Hz, 1H), 4.42 (s, 1H), 4.12 (q, J = 6.5 Hz, 1H), 3.97 (q, J = 5.0 Hz, 1H), 3.78 - 3.85 (m, 5H), 3.72 (q, J = 6.3 Hz, 1H), 3.01 - 3.05 (m, 1H), 2.93 (d, J = 18.3 Hz, 1H), 2.44 (dd, J = 12.1, 4.3 Hz, 1H), 2.33 (s, 3H), 2.27 (dd, J = 18.2, 5.4 Hz, 1H), 2.09 - 2.17 (m, 2H), 1.79 (dt, J = 12.3, 4.9 Hz, 1H), 1.56 - 1.66 (m, 2H), 1.41 - 1.50 (m, 2H), 1.08 (td, J = 12.7, 2.2 Hz, 1H); ¹³C NMR (CDCl₃, 125.5 MHz): 146.6, 142.1, 129.2, 126.5, 118.6, 113.4, 108.6, 94.4, 66.4, 64.9, 59.5, 56.5, 47.1, 43.6, 42.9, 42.6, 36.5, 33.4, 22.3, 20.1; MS (El) m/z (%): 344 (23.3), 343 (100.0), 342 (13.4), 329 (14.4), 256 (11.4), 244 (17.2), 198 (11.1), 99 (8.6), 59 (16.5), 55 (12.0); HRMS (El) calcd for C₂₀H₂₉NO₄: 343.1784; found 343.1777.

Example 3. Hydrocodone (4) One pot procedure from 10

[0050] A solution of 10 (45 mg, 0.13 mmol, 1.0 eq) in MeOH (90 μl) was treated with Pt/C (10%) under 1 atmosphere of H₂ for 12 hours. 25% v/v H₂SO₄/ZMeOH (0.5 ml) was added to the reaction solution, which was stirred for three hours. The pH of the solution was adjusted to >11 with saturated aqueous K₂CO₃ and extracted with CHCl₃ (5 ml x 3). The combined organic extracts were dried over Na₂SO₄, filtered, concentrated and the crude material purified by column chromatography (CHCl₃:MeOH:NH₂OH - 98:2:1) to yield hydrocodone in 75% yield.

[0051] All analytical data generated for hydrocodone synthesized in this manner is identical with that of an authentic sample of hydrocodone.

42
Example 4. One pot procedure from 3

[0052] Thebaine (100 mg, 0.32 mmol, 1.0 eq) was dissolved in THF (1 ml) and H₂O (1 ml) added. To this solution Pd(OAc)₂ (72 mg, 0.32 mmol, 1.0 eq) was added. After two hours at room temperature the orange/red reaction solution contains no thebaine as evidenced by TLC. H₂ was added to the reaction vessel by use of a balloon and the reaction stirred for a further 4 hours. Removal of the balloon and filtration of the reaction through a plug of silica (CHCl₃:MeOH:NH₄OH 92:8:1) gave the crude products 4 and 20 in a ratio of 1:1.34. Purification was achieved by column chromatography CHCl₃:MeOH:NH₄OH - 98:2:1 to yield 4 in 43% and 20 in 52%.

[0053] All analytical data generated for hydrocodone synthesized in this manner is identical with that of an authentic sample of hydrocodone. Data for 20 is identical to that published in the literature.¹¹ β-dihydro-thebainone (20) FTIR (Vmax cm⁻¹) film: 3401, 2935, 2839, 2243, 1710, 1604, 1583, 1483, 1439, 1277, 1228, 1062, 922; ¹H NMR (CDCl₃, 600 MHz): 6.68 (d, J = 8.3 Hz, 1H), 6.60 (d, J = 8.3 Hz, 1H), 4.25 (dd, J = 13.3, 2.5 Hz, 1H), 3.82 (s, 3H), 3.13 - 3.16 (m, 1H), 2.98 (d, J = 18.5 Hz, 1H), 2.76 (dd, J = 18.5, 6.0 Hz, 1H), 2.60 - 2.64 (m, 1H), 2.46 (s, 3H), 2.41 - 2.45 (m, 1H), 2.31 (dt, J = 12.8, 3.2 Hz, 1H), 2.23 - 2.28 (m, 2H), 2.12 (td, J = 12.0, 4.1 Hz, 1H) 2.05 (s, 1H), 1.84 - 1.93 (m, 3H), 1.68 (qd, J = 13.2, 5.0 Hz, 3H); ¹³C NMR (CDCl₃, 125.5 MHz): 210.7, 145.1, 144.8, 129.7, 122.6, 118.5, 109.0, 57.0, 56.1, 50.4, 46.4, 44.3, 42.1, 41.0, 40.9, 38.0, 27.0, 23.8; MS (El)ATVz (%): 302 (11.6), 301 (56.2), 300 (18.0), 242 (10.3), 164 (53.3), 88 (11.2), 86 (64.3), 84 (100.0), 60 (19.3), 59 (16.7), 49 (19.7), 47 (23.5), 45 (24.7), 44 (13.3), 43 (34.7), 42 (17.8); HRMS (El) calcd for C₁₃H₂₈NO₃: 301.1678; found 301.1671.

Example 5. 1,7,10-tribromo- Neopinone ethylene glycol ketal (14)

[0054] Thebaine (50 mg, 0.16 mmol, 1.0 eq) was dissolved in THF (1 ml) and ethylene glycol (100 mg, 1.61 mmol, 10.0 eq) added. Br₃ (103 mg, 0.64 mmol, 4.0 eq) was added in a single portion and the reaction stirred for 10 hours. Na₂SO₃ (sat. aq. solution) was added to remove excess bromine. Reaction cooled to 0 °C and the pH adjusted to >11 with saturated aqueous K₂CO₃. The reaction solution was extracted with CHCl₃ (5 x 5ml), the organic extracts were combined and dried.
over Na₂SO₄. Chromatography of the crude residue with 200:1 CHCl₃:MeOH provides the title compound in 27% yield.

[0055] |IR (νₘₐₓ, crd ¹) film: 2391, 2937, 2891, 1654, 1632, 1611, 1487, 1435, 1287, 1203, 1160, 1125, 1089, 1051, 909; ¹H NMR (CDCl₃, 600 MHz): 6.92 (s, 1H), 5.25 (s, 1H), 4.61 (d, J = 6.4 Hz, 1H), 3.94 - 3.99 (m, 1H), 3.88 (s, 3H), 3.81 - 3.87 (m, 1H), 3.61 - 3.64 (m, 1H), 3.11 (d, J = 18.6 Hz, 1H), 2.70 - 2.79 (m, 1H), 2.56 - 2.68 (m, 2H), 2.50 (s, 3H), 2.37 - 2.43 (m, 1H), 1.76 (dd, J = 12.8, 2.3 Hz, 1H); ¹³C NMR (CDCl₃, 125.5 MHz): 145.2, 143.1, 132.3, 126.5, 117.0, 116.3, 112.0, 98.4, 92.0, 77.2, 64.4, 62.0, 60.1, 57.0, 49.5, 46.4, 45.3, 41.9, 35.1, 30.3; MS (El) m/z (%): 344 (23.3), 343 (100.0), 342 (13.4), 329 (14.4), 256 (11.4), 244 (17.2), 198 (11.1), 99 (86.9), 59 (16.5), 55 (12.0); HRMS (El) calcd for C₂₀H₂₅NO₄: 343.1784; found 343.1777

Example 6. Pd/C hydrogenation of thebaine

[0056] Thebaine (100 mg, 0.32 mmol) was dissolved in 20% HCl (500 µl) and Pd/C (10%, 5 mg) added. The reaction was stirred under 1 atmosphere of H₂ at room temperature for 12 hours, after which time the reaction was basified with NH₄OH. The reaction mixture was extracted three times with CHCl₃ and the combined organic layers were dried over Na₂SO₄ and filtered. Column chromatography (CHCl₃:MeOH:NH₄OH 98:2:1) provided pure samples of hydrocodone, β-dihydrothebainone and tetrahydrothebaine in various ratios depending on the conditions applied.

[0057] One or more currently preferred embodiments have been described by way of example. It will be apparent to persons skilled in the art that a number of variations and modifications can be made without departing from the scope of the invention as defined in the claims.
References:
WHAT IS CLAIMED IS:

1. A method of converting thebaine to morphine derivative, said method comprising the steps of:
   a. combining thebaine with an organic compound having at least one hydroxyl group in the presence of a catalyst to obtain a ketal intermediate;

b. exposing the ketal intermediate to hydrogenation to obtain a hydrogenated intermediate; and

c. hydrolyzing the hydrogenated intermediate to obtain a morphine derivative.

2. A method according to claim 1, wherein the morphine derivative is selected from the group consisting of hydrocodone, hydromorphone, oxycodone, oxymorphone, nalbuphine, naloxone, naltrexone, buprenorphine and etorphine.

3. A method according to claim 2, wherein the morphine derivative is hydrocodone.

4. A method according to claim 1, wherein the hydrogenation and hydrolyzation steps are combined in a one-pot procedure.

5. A method according to claim 1, wherein the organic compound is an aliphatic alcohol other than methanol.

6. A method according to claim 1, wherein the organic compound is a diol.

7. A method according to claim 4 wherein the diol is ethylene glycol.
8. A method according to claim 5 wherein the diol is 2,3-dimethyl-1,4-butane diol.

9. A method according to claim 1 wherein the catalyst is a protic or Lewis acid.

10. A method according to claim 7 wherein the catalyst is p-toluenesulfonic acid.

11. A method according to claim 1 wherein the catalyst is a metal catalyst.

12. A method according to claim 11 wherein the catalyst is selected from the group consisting of: Pd, Pd(OAc)$_2$, PdCl$_2$, PdBr$_2$, PdO, RhCl$_3$, PtO$_2$, RhCl(PPh$_3$)$_3$, Rh/Al, Pd/C, Pt/C, Pd on CaCO$_3$/Pb, Pd/Al, PtCl$_2$, PtCl$_4$, Al, Zn, Fe, Sn, Ru, Co, Rh, Ir, Ni, Pd, Pt, Ti, Os, Cu.

13. A method according to claim 12 wherein the catalyst is selected from the group consisting of: Pd(OAc)$_2$, PdCl$_2$, PdBr$_2$, PdO, RhCl$_3$, PtO$_2$, RhCl(PPh$_3$)$_3$, Rh/Al, Pd/C, Pt/C, Pd on CaCO$_3$/Pb (Lindlar), Pd/Al, PtCl$_2$, PtCl$_4$.

14. A method according to claim 13 wherein the catalyst is selected from the group consisting of: Al, Zn, Fe, Sn, Ru, Co, Rh, Ir, Ni, Pd, Pt.

15. A method according to claim 12 wherein the catalyst is selected from the group consisting of: Ti, Os, Cu.

16. A method of producing a ketal derivative from thebaine, comprising combining thebaine with an organic compound having at least one hydroxyl group in the presence of a catalyst to obtain a ketal intermediate.

17. A ketal derivative of thebaine, comprising a structure selected from the group below:
wherein V is C$_2$–C$_{10}$ alkyl
W is H or C$_1$–C$_{10}$ alkyl
X is H or C$_i$–C$_{10}$ alkyl, cyclopropylmethyl, cyclobutylmethyl, propenyl, acyl (C1–C10) or carboxy (C1–C10)
Y is H or I or Br or Cl or F
R is H, alkyl (C1–C10), hydroxyl alkyl (C1–C10), or alkoxy alkyl;
Ri is H, alkyl (C1–C10), hydroxyl alkyl (C1–C10), or alkoxy alkyl;
Z is O, S or N; and
wherein R and R1 may be the same or different.

18. A ketal derivative according to claim 17 wherein Z is O.

19. A ketal derivative according to claim 17 wherein W is CH3.

20. A ketal derivative according to claim 17 comprising an unsaturated ethylene glycol ketal of neopinone.

21. A ketal derivative according to claim 17 wherein Y is Br.

22. A hydrogenated ketal intermediate obtained according to the method of claim 1. 

23. A hydrogenated ketal intermediate according to claim 22 comprising compound 17.
24. An alkyl ammonium salt of a ketal as defined in claim 17.

25. An alkyl ammonium salt according to claim 24 wherein the salt is allyl derived.

26. An alkyl ammonium salt according to claim 24 wherein the salt is methylene cyclopropyl derived.

27. A method of obtaining a morphine derivative from thebaine, said method comprising:
   a. combining thebaine with an organic compound having at least one hydroxyl group in the presence of a pseudo-proton to obtain a ketal intermediate; and
   b. subjecting the intermediate to a one pot hydrogenation and hydrolysis to obtain the morphine derivative.

28. A method according to claim 24 wherein the pseudo proton is provided by a halogen.

29. A method according to claim 25 wherein the halogen is selected from the group consisting of bromine, chlorine and iodine.

30. A method according to claim 26 wherein the halogen is bromine.

31. A method according to claim 24 wherein the pseudo proton is provided by a transition metal catalyst.

32. A method according to claim 24 wherein the morphine derivative is hydrocodone, hydromorphone, oxycodone or oxymorphone.

33. A method according to claim 29 wherein the derivative is hydrocodone.
34. A one pot method of obtaining hydrocodone from thebaine comprising exposing thebaine to Pd(OAc)$_2$ in the presence of an organic compound having at least one hydroxyl group.

35. A method according to claim 31 wherein the organic compound having at least one hydroxyl group is ethylene glycol.

36. A one pot method for the conversion of thebaine to hydrocodone comprising exposing thebaine to Pd(OAc)$_2$ in the presence of aqueous THF followed by hydrogenation.

37. A one pot method for obtaining hydrocodone from thebaine comprising exposing thebaine to an acid under about one atmosphere of hydrogen in the presence of a catalyst under aqueous conditions.

38. The method of claim 34 wherein the acid comprises HCl or H$_2$SO$_4$.

39. A method of converting thebaine to a C14 hydroxylated derivative, said method comprising the steps of:
   i) exposing thebaine to an organic compound containing at least one hydroxyl group in the presence of a catalyst to obtain a ketal intermediate;
   ii) subjecting the derivative to hydrogenation and hydrolysis; and
   iii) oxidation of a hydrogen to a hydroxyl.

40. A method of converting thebaine to a C14 hydroxylated derivative, said method comprising the steps of:
   i) exposing thebaine to an organic compound containing at least one hydroxyl group in the presence of a catalyst to obtain a ketal intermediate;
ii) converting the ketal to a 14-hydroxy ketal; and

iii) subjecting the 14-hydroxyketal to hydrolysis.
INTERNATIONAL SEARCH REPORT

International application No
PCT/CA2008/001178

A CLASSIFICATION OF SUBJECT MATTER
IPC C07D 489/02 (2006 01) , C07D 489/04 (2006 01)
According to International Patent Classification (FPC) or to both national classification and IPC

B FIELDS SEARCHED
Minimum documentation searched (classification system followed by classification symbols)
IPC C07D 489/02 (2006 01) , C07D 489/04 (2006 01)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic database(s) consulted during the international search (name of database(s) and, where practicable, search terms used)
Canadian Patent Database, PubMed, Delphion, STN (search terms "converting thebain to morphine derivative", "converting thebaine to hydrocodone", "synthesis of hydrocodone", "hydrogenation of thebaine", "hydrogynation of neopomone ketal", "ketal derivative of thebaine", "neopomone ketal" and "dihydronopomone ketal")

C DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category*</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td>OSA, Y et al 'A New Useful Conversion Method of Naltrexone to 14-Deoxynaltrexone' Heterocycles, vol 69, 2006, pp 271-282 (see Scheme 4)</td>
<td>1-4, 11, 16-20, 22, 23, 27, 31-33, 37</td>
</tr>
<tr>
<td>X</td>
<td>BARBER, R B et al 'Conversion of Thebaine to Codeine' J Med Chem, vol 19, no 10, 1996, pp 1175-1 180 (see entire document)</td>
<td>16</td>
</tr>
<tr>
<td>X</td>
<td>WO2006/138020A2 (WANG, P X et al ) 28 December 2006 (28-12-2006) (see compound of Formula 29 wherein R1 and R2 are CH3, R3 is a ketal, R = is H, Br or Cl, R' = is H, X is H, Br or Cl and the '.....' line is an optional double bond)</td>
<td>17-23</td>
</tr>
<tr>
<td>X</td>
<td>US5668285 (RICE, K C et al ) 16 September 1997 (16-09-1997) (see compound (H))</td>
<td>22-23</td>
</tr>
</tbody>
</table>

Further documents are listed in the continuation of Box C [X] See patent family annex

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
X document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
Y document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents such combination being obvious to a person skilled in the art
& document member of the same patent family

Date of the actual completion of the international search
August 2008 (14-08-2008)

Date of mailing of the international search report
September 2008 (26-09-2008)

Name and mailing address of the ISA/CA
Canadian Intellectual Property Office
Place du Portage I, Cl 14 - 1st Floor, Box PCT
50 Victoria Street
Gatineau, Quebec K1A 0C9
Facsimile No 001-819-953-2476

Authorized officer
Gerald McManus 819- 956-6126

Form PCT/ISA/210 (second sheet ) (July 2008)
This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. [ ] Claim Nos because they relate to subject matter not required to be searched by this Authority, namely

2. [ ] Claim Nos because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically

3. [ ] Claim Nos because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6 4(a)

This International Searching Authority found multiple inventions in this international application, as follows:

**Group A** Claims 1-36 and 38-40 are directed to a method for converting thebaine to morphine derivatives comprising combining thebaine with an organic compound having at least one hydroxyl group in the presence of a catalyst to obtain a ketal intermediate, exposing said ketal to hydrogenation then to hydrolysis, and

**Group B** Claim 37 is directed to a method for converting thebaine to hydrocodone comprising exposing thebaine to an acid under about one atmosphere of hydrogen in the presence of a catalyst under aqueous conditions

1. [ ] As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims

2. [X] As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees

3. [ ] As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claim Nos

4. [ ] No required additional search fees were timely paid by the applicant Consequently, this international search report is restricted to the invention first mentioned in the claims, it is covered by claim Nos

**Remark on Protest**

[ ] The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee

[ ] The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation

[ ] No protest accompanied the payment of additional search fees
<table>
<thead>
<tr>
<th>Patent Document Cited in Search Report</th>
<th>Publication Date</th>
<th>Patent Family Member(s)</th>
<th>Publication Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>US4277604</td>
<td>07-07-1981</td>
<td>NONE</td>
<td></td>
</tr>
<tr>
<td>WO2006138020</td>
<td>28-12-2006</td>
<td>AU2006259780 A1</td>
<td>28-12-2006</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA2610859 A1</td>
<td>28-12-2006</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CN101 198612 A</td>
<td>11-06-2008</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP1893616 A2</td>
<td>05-03-2008</td>
</tr>
<tr>
<td>US5668285</td>
<td>16-09-1997</td>
<td>AT178329 T</td>
<td>15-04-1999</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU642447 B2</td>
<td>21-10-1993</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU6742690 A</td>
<td>16-05-1991</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA2067200 A1</td>
<td>17-04-1991</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DE69033035 D1</td>
<td>06-05-1999</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DE69033035T2</td>
<td>05-08-1999</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DK496830 T3</td>
<td>11-10-1999</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP0496830 A1</td>
<td>05-08-1992</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ES2129395 T3</td>
<td>16-06-1999</td>
</tr>
<tr>
<td></td>
<td></td>
<td>GR3030101 T3</td>
<td>30-07-1999</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP2694156 B2</td>
<td>24-12-1997</td>
</tr>
</tbody>
</table>